Researchers have determined how children's immune systems react to different kinds of cancer depending on their age. The study reveals significant differences between the immune response of children and adults, and has the potential to lead to new tailored treatments for children with cancer.

A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing certain receptors from their surfaces and blocking cancer gene activity, according to a preclinical study.

Long classified as a subset of common liver cancer, FLC should be considered its own unique disease. Now researchers are testing a combination drug therapy that targets FLC tumors.

The tissue adjacent to a tumor behaves differently than areas farther away: The tumor's cancerous cells influence their surroundings, blocking the body's immune defenses and creating a sort of haven in which the tumor can grow. Treatments that target some of these pro-tumor actions are effective in a number of cancers, but only for some patients; in others, these treatments have little effect. Researchers have now developed a new approach that simultaneously targets several of these pro-tumor actions at once, which they have demonstrated can effectively reduce tumor growth across several types of cancers. Their new findings point to a potential new treatment that may benefit more patients than current therapeutic options.

Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.

Scientists have used deep learning to design new proteins that bind to complexes involving other small molecules like hormones or drugs, opening up a world of possibilities in the computational design of molecular interactions for biomedicine.